Alessandra Sottini Ruggero Capra Cinzia Zanotti Marco Chiarini Federico Serana Doris Ricotta Luigi Caimi Luisa Imberti
10.1371/journal.pone.0034493
PLoS One
2012;7(4):e34493.
CC BY
https://pubmed.ncbi.nlm.nih.gov/22496817/
Antibodies, Monoclonal, Humanized / adverse effects B-Lymphocytes / pathology Leukoencephalopathy, Progressive Multifocal / immunology Multiple Sclerosis / immunology T-Lymphocytes / pathology
Antibodies, Monoclonal, Humanized / adverse effects B-Lymphocytes / pathology Leukoencephalopathy, Progressive Multifocal / immunology Multiple Sclerosis / immunology T-Lymphocytes / pathology Case Reports Adult B-Lymphocytes / immunology B-Lymphocytes / metabolism Case-Control Studies Female Humans Leukoencephalopathy, Progressive Multifocal / chemically induced Leukoencephalopathy, Progressive Multifocal / pathology Male Middle Aged Multiple Sclerosis / complications Multiple Sclerosis / therapy Natalizumab T-Lymphocytes / immunology T-Lymphocytes / metabolism Young Adult Antibodies, Monoclonal, Humanized Natalizumab
PMC3319584
22496817
Pre-existing T- and B-cell defects in one progressive multifocal leukoencephalopathy patient
2012